According to the recent research report titled ‘North America Electrophysiology Market Size By End-use, By Product, By Indication, Industry Analysis Report, Country Outlook, Application Potential, Competitive Market Share & Forecast, 2021 – 2027’, available with Market Study Report, North America electrophysiology market is projected to accumulate more than USD 3.5 billion by the year 2027.
 

Rising cases of various cardiac arrhythmias, collective inclination towards using electrophysiology catheter ablation, technological advancements in this business space, and subsequent innovative product launches are the key factors driving North America electrophysiology market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3212723/
 

Speaking of recent events, the outbreak of COVID-19 pandemic has negatively impacted the healthcare sector. It has adversely affected the sales of various companies, and consequently the revenue accrued by elective and non-emergent procedures, thereby restraining the market growth to some extent.
 

However, with rising incidence of heart rhythm disorders and weakening prevalence of coronavirus infection, North America electrophysiology industry is expected to recover and expand steadily in the near future.
 

Based on product type, EP laboratory devices segment generated about USD 190 million for the overall in 2020, owing to consistent innovations in mapping and navigation systems. Citing an instance, in March 2020, the FDA granted Stereotaxis a 510(k) for the Genesis RMN System. Such developments combined with the rising prevalence of cardiovascular diseases is likely to propel North America electrophysiology industry expansion.
 

Considering the indication channel, ventricular tachycardia segment held approximately 12% market share in 2020. Experts cite that ventricular tachycardia causes nearly 300,000 deaths annually in the U.S. and is one of the key factors leading to sudden cardiac mortalities, further necessitating immediate medical attention for such patients, which in turn is fueling the adoption of electrophysiology treatment options in North America.
 

Coming to end user scope, catheterization laboratories segment held about USD 150 million market share in terms of revenue in 2020 and is expected to expand continuously through 2027, as it provides necessary medical intervention to cardiac patients as well as efficient safety protocol. Moreover, decline in prevalence of COVID-19 and relaxing restrictions will also add to the segmental growth.
 

Regionally, Canada electrophysiology industry size is predicted to expand at 10.7% CAGR through 2027, owing to progressing interventional and electrophysiology procedures in the region. Lately, customers have been drawn to Canada due to its large pool of qualified cardiologists and specialized equipment in hospitals and catheterization laboratories. Furthermore, increasing pervasiveness of cardiac arrhythmias is also expected to contribute to the industry outlook in Canada.
 

Major companies swaying North America electrophysiology market trends are Microport Scientific Corporation, Stereotaxis Inc., Siemens Healthineers AG, Medtronic plc, Koninklijke Philips N.V., Johnson & Johnson, GE Healthcare, Boston Scientific Corporation, Biotronik SE & Co. KG, and Abbott Laboratories.